Crest Pharma Ltd
Joseph Birkett is currently working as a Director and Owner in Crest Pharma Ltd. He has Very experienced drug developer with over 15 years experience across all phases (I-IV and post-marketing). He has extensive experience in haematology (NHL/CLL) and solid tumours. Experienced in the clinical development of Tyrosine Kinase inhibitors (Global clinical lead for Btk ONO-4059), Monoclonal antibodies (lead clinical scientist for pivotal Phase I/II GA101/Obinutuzumab studies), ASOs (Survivin and Eif4e), DNA repair. His experience includes in working with patient advocacy groups to enhance patient and doctor understanding of new and existing therapy options.
Pre-clinical studies, new therapies for the treatment of cancer, drug development process.